18.03 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
Viridian Therapeutics, Inc. Common Stock
VRDNNASDAQ • USD
18.38
↗ 0.34 (1.91%)
POST MARKET (AS OF 05:58 PM EDT)
Post Market
AS OF 05:58 PM EDT
18.38
↗ 0.34 (1.91%)
Market: CLOSED
Viridian Therapeutics, Inc. Common Stock (VRDN) trades at $18.02 per share. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, VRDN trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Jul 17, 2026.
Open?$17.72
High?$18.24
Low?$17.54
Prev. Close?$18.03
Volume?2.1M
Avg. Volume?2.2M
VWAP?$17.90
Rel. Volume?0.97x
Bid / Ask
Bid?$15.42 × 100
Ask?$21.43 × 100
Spread?$6.01
Midpoint?$18.43
Valuation & Ratios
Market Cap?2.0B
Shares Out?103.1M
Float?86.3M
Float %?90.5%
P/E Ratio?N/A
P/B Ratio?3.13
EPS?-$2.75
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Employees
252
Market Cap
2.0B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-06-18
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: 617.272.4600
WALTHAM, MA 02453
Phone: 617.272.4600
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?97
Momentum?62
Short Sent.?21
Piotroski F-Score?1/9Weak
Altman Z-Score?4.84Safe
Confidence?51%Low
Short InterestSqueeze Risk
Short % of Float?20.09%Squeeze Risk
Short Interest?17.3M
Days to Cover?5.6
Free Float86.3M
Avg Daily Volume3.1M
Settlement Date2026-06-30
Financial Health
Current Ratio?15.15Strong
Quick Ratio?15.15Strong
Cash Ratio?3.40Strong
Debt/Equity?0.14Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?3.13FAIR▾
Peers100
S&P54
P/S?28.07HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-4.9CHEAP▾
S&P97
EV/Sales?26.81HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-47.7%WEAK▾
S&P3
ROA?-38.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-303824000
Enterprise Value?$1.9B
Fundamentals ratios updated end of day